文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

多组分干预预防虚弱老年人活动障碍:随机对照试验(SPRINTT 项目)。

Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project).

机构信息

Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome, Italy.

Department of Geriatrics and Orthopaedics, Università Cattolica del Sacro Cuore, Rome, Italy.

出版信息

BMJ. 2022 May 11;377:e068788. doi: 10.1136/bmj-2021-068788.


DOI:10.1136/bmj-2021-068788
PMID:35545258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9092831/
Abstract

OBJECTIVE: To determine whether a multicomponent intervention based on physical activity with technological support and nutritional counselling prevents mobility disability in older adults with physical frailty and sarcopenia. DESIGN: Evaluator blinded, randomised controlled trial. SETTING: 16 clinical sites across 11 European countries, January 2016 to 31 October 2019. PARTICIPANTS: 1519 community dwelling men and women aged 70 years or older with physical frailty and sarcopenia, operationalised as the co-occurrence of low functional status, defined as a short physical performance battery (SPPB) score of 3 to 9, low appendicular lean mass, and ability to independently walk 400 m. 760 participants were randomised to a multicomponent intervention and 759 received education on healthy ageing (controls). INTERVENTIONS: The multicomponent intervention comprised moderate intensity physical activity twice weekly at a centre and up to four times weekly at home. Actimetry data were used to tailor the intervention. Participants also received personalised nutritional counselling. Control participants received education on healthy ageing once a month. Interventions and follow-up lasted for up to 36 months. MAIN OUTCOME MEASURES: The primary outcome was mobility disability (inability to independently walk 400 m in <15 minutes). Persistent mobility disability (inability to walk 400 m on two consecutive occasions) and changes from baseline to 24 and 36 months in physical performance, muscle strength, and appendicular lean mass were analysed as pre-planned secondary outcomes. Primary comparisons were conducted in participants with baseline SPPB scores of 3-7 (n=1205). Those with SPPB scores of 8 or 9 (n=314) were analysed separately for exploratory purposes. RESULTS: Mean age of the 1519 participants (1088 women) was 78.9 (standard deviation 5.8) years. The average follow-up was 26.4 (SD 9.5) months. Among participants with SPPB scores of 3-7, mobility disability occurred in 283/605 (46.8%) assigned to the multicomponent intervention and 316/600 (52.7%) controls (hazard ratio 0.78, 95% confidence interval 0.67 to 0.92; P=0.005). Persistent mobility disability occurred in 127/605 (21.0%) participants assigned to the multicomponent intervention and 150/600 (25.0%) controls (0.79, 0.62 to 1.01; P=0.06). The between group difference in SPPB score was 0.8 points (95% confidence interval 0.5 to 1.1 points; P<0.001) and 1.0 point (95% confidence interval 0.5 to 1.6 points; P<0.001) in favour of the multicomponent intervention at 24 and 36 months, respectively. The decline in handgrip strength at 24 months was smaller in women assigned to the multicomponent intervention than to control (0.9 kg, 95% confidence interval 0.1 to 1.6 kg; P=0.028). Women in the multicomponent intervention arm lost 0.24 kg and 0.49 kg less appendicular lean mass than controls at 24 months (95% confidence interval 0.10 to 0.39 kg; P<0.001) and 36 months (0.26 to 0.73 kg; P<0.001), respectively. Serious adverse events occurred in 237/605 (39.2%) participants assigned to the multicomponent intervention and 216/600 (36.0%) controls (risk ratio 1.09, 95% confidence interval 0.94 to 1.26). In participants with SPPB scores of 8 or 9, mobility disability occurred in 46/155 (29.7%) in the multicomponent intervention and 38/159 (23.9%) controls (hazard ratio 1.25, 95% confidence interval 0.79 to 1.95; P=0.34). CONCLUSIONS: A multicomponent intervention was associated with a reduction in the incidence of mobility disability in older adults with physical frailty and sarcopenia and SPPB scores of 3-7. Physical frailty and sarcopenia may be targeted to preserve mobility in vulnerable older people. TRIAL REGISTRATION: ClinicalTrials.gov NCT02582138.

摘要

目的:确定基于体力活动并辅以技术支持和营养咨询的多组分干预是否可以预防身体虚弱和肌少症的老年人发生移动障碍。

设计:评估人员设盲、随机对照试验。

地点:16 个临床地点分布在 11 个欧洲国家,2016 年 1 月至 2019 年 10 月 31 日。

参与者:1519 名 70 岁或以上、身体虚弱且患有肌少症的社区居住的男性和女性,身体虚弱和肌少症的定义为短体适能表现测试(SPPB)评分 3 至 9 分、四肢瘦体重低以及能够独立行走 400 米的情况同时出现。760 名参与者被随机分配到多组分干预组,759 名参与者接受健康老龄化教育(对照组)。

干预措施:多组分干预包括每周两次在中心进行中等强度的体力活动,以及在家中每周最多进行四次。使用活动数据来定制干预措施。参与者还接受个性化的营养咨询。对照组参与者每月接受一次健康老龄化教育。干预和随访时间最长为 36 个月。

主要结局指标:主要结局是移动障碍(无法在 15 分钟内独立行走 400 米)。持续性移动障碍(无法连续两次行走 400 米)以及 24 个月和 36 个月时身体表现、肌肉力量和四肢瘦体重的变化是作为预先计划的次要结局进行分析的。主要比较是在基线 SPPB 评分为 3-7(n=1205)的参与者中进行的。对于 SPPB 评分为 8 或 9(n=314)的参与者,单独进行了探索性分析。

结果:1519 名参与者(1088 名女性)的平均年龄为 78.9(标准差 5.8)岁。平均随访时间为 26.4(标准差 9.5)个月。在 SPPB 评分为 3-7 的参与者中,移动障碍发生在多组分干预组的 605 名(46.8%)参与者中和对照组的 600 名(52.7%)参与者中(危险比 0.78,95%置信区间 0.67 至 0.92;P=0.005)。持续性移动障碍发生在多组分干预组的 605 名(21.0%)参与者中和对照组的 600 名(25.0%)参与者中(0.79,0.62 至 1.01;P=0.06)。24 个月和 36 个月时,多组分干预组的 SPPB 评分分别提高了 0.8 分(95%置信区间 0.5 至 1.1 分;P<0.001)和 1.0 分(95%置信区间 0.5 至 1.6 分;P<0.001)。24 个月时,女性参与者中,多组分干预组的握力下降幅度小于对照组(0.9 千克,95%置信区间 0.1 至 1.6 千克;P=0.028)。多组分干预组的女性参与者在 24 个月和 36 个月时的四肢瘦体重分别比对照组少 0.24 千克和 0.49 千克(95%置信区间 0.10 至 0.39 千克;P<0.001)和 0.26 千克至 0.73 千克(P<0.001)。多组分干预组的 605 名参与者(39.2%)和对照组的 600 名参与者(36.0%)发生了严重不良事件(风险比 1.09,95%置信区间 0.94 至 1.26)。在 SPPB 评分为 8 或 9 的参与者中,移动障碍发生在多组分干预组的 155 名(29.7%)参与者中和对照组的 159 名(23.9%)参与者中(危险比 1.25,95%置信区间 0.79 至 1.95;P=0.34)。

结论:多组分干预可降低身体虚弱和肌少症且 SPPB 评分为 3-7 的老年人发生移动障碍的发生率。身体虚弱和肌少症可能是针对易受伤害的老年人保持移动能力的靶点。

试验注册:ClinicalTrials.gov NCT02582138。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b00/9092831/3f77accf172e/berr068788.f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b00/9092831/75a8b225a30b/berr068788.f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b00/9092831/20dcb5327808/berr068788.f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b00/9092831/3f77accf172e/berr068788.f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b00/9092831/75a8b225a30b/berr068788.f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b00/9092831/20dcb5327808/berr068788.f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b00/9092831/3f77accf172e/berr068788.f3.jpg

相似文献

[1]
Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project).

BMJ. 2022-5-11

[2]
The sarcopenia and physical frailty in older people: multi-component treatment strategies (SPRINTT) project: description and feasibility of a nutrition intervention in community-dwelling older Europeans.

Eur Geriatr Med. 2021-4

[3]
The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) randomized controlled trial: design and methods.

Aging Clin Exp Res. 2017-2

[4]
A multicomponent frailty intervention for socioeconomically vulnerable older adults: a designed-delay study.

Clin Interv Aging. 2018-9-19

[5]
The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) randomized controlled trial: Case finding, screening and characteristics of eligible participants.

Exp Gerontol. 2018-9-24

[6]
The Effectiveness of a PRoactive Multicomponent Intervention Program on Disability in Independently Living Older People: A Randomized Controlled Trial.

J Nutr Health Aging. 2018

[7]
Combinations of Sarcopenia Diagnostic Criteria by Asian Working Group of Sarcopenia (AWGS) 2019 Guideline and Incident Adverse Health Outcomes in Community-Dwelling Older Adults.

J Am Med Dir Assoc. 2023-8

[8]

2022-12

[9]
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

Cochrane Database Syst Rev. 2022-2-1

[10]
Effectiveness of a complex intervention of group-based nutrition and physical activity to prevent frailty in pre-frail older adults (SUPER): a randomised controlled trial.

Lancet Healthy Longev. 2022-8

引用本文的文献

[1]
The Influence of Muscle Morphology on Oncological Outcomes: A Review.

J Frailty Sarcopenia Falls. 2025-9-1

[2]
What Do We Know About Prevention of Frailty in Women?

Am J Lifestyle Med. 2025-8-29

[3]
Towards a core outcome set for sarcopenia intervention studies: a scoping review identifying the most frequently reported outcomes across randomized controlled trials in sarcopenia.

Eur Geriatr Med. 2025-8-12

[4]
Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: a multicenter observational trial (SARA-OBS).

BMC Geriatr. 2025-8-4

[5]
The Effects of Pulsed Electromagnetic Field (PEMF) on Muscular Strength, Functional Performance and Depressive Symptoms in Elderly Adults with Sarcopenia: A Short-Term Intervention.

Life (Basel). 2025-7-16

[6]
Preventative approaches to falls and frailty.

Osteoporos Sarcopenia. 2025-6

[7]
Comparison of muscle strength and power in the short physical performance battery for predicting negative outcomes in older adults with mobility limitations.

J Nutr Health Aging. 2025-7-15

[8]
Modulating Ferroptosis in Aging: The Therapeutic Potential of Natural Products.

J Aging Res. 2025-7-3

[9]
Effects of two-year adapted physical exercise program and nutritional counselling on cardio-sarcopenia syndrome in older adults with low muscle function.

Eur Rev Aging Phys Act. 2025-7-4

[10]
Association of personalized dietary advice aiming to increase protein intake with macronutrient intake of community-dwelling older adults: a secondary analysis of the PROMISS RCT.

Eur Geriatr Med. 2025-7-1

本文引用的文献

[1]
Effects of Vivifrail multicomponent intervention on functional capacity: a multicentre, randomized controlled trial.

J Cachexia Sarcopenia Muscle. 2022-4

[2]
Effects of resistance training in healthy older people with sarcopenia: a systematic review and meta-analysis of randomized controlled trials.

Eur Rev Aging Phys Act. 2021-11-11

[3]
International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines.

J Nutr Health Aging. 2021

[4]
Effects and Moderators of Exercise on Sarcopenic Components in Sarcopenic Elderly: A Systematic Review and Meta-Analysis.

Front Med (Lausanne). 2021-5-19

[5]
Physical Rehabilitation for Older Patients Hospitalized for Heart Failure.

N Engl J Med. 2021-7-15

[6]
Physical Functional Assessment in Older Adults.

J Frailty Aging. 2021

[7]
Heterogeneity of Aging: Individual Risk Factors, Mechanisms, Patient Priorities, and Outcomes.

J Am Geriatr Soc. 2021-3

[8]
Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial.

JAMA Netw Open. 2020-10-1

[9]
Sex-and race-specific associations of protein intake with change in muscle mass and physical function in older adults: the Health, Aging, and Body Composition (Health ABC) Study.

Am J Clin Nutr. 2020-7-1

[10]
Nutritional interventions to improve muscle mass, muscle strength, and physical performance in older people: an umbrella review of systematic reviews and meta-analyses.

Nutr Rev. 2021-1-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索